Skip to main content
Signal8
Grayson Paul A. profile photo

Paul A. Grayson

CIK: 0001861554

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (33.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Skye Bioscience, Inc. logo
SKYE

Skye Bioscience, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

  • Skye Bioscience, Inc. logo
    SKYE

    Skye Bioscience, Inc.

    Mar 31, 2026
    Award(A)

    Stock Option (Right to Buy)

    Direct
    75K shares-
  • Skye Bioscience, Inc. logo
    SKYE

    Skye Bioscience, Inc.

    Feb 6, 2026
    Award(A)

    Stock Option (Right to Buy)

    Direct
    35K shares-
  • Skye Bioscience, Inc. logo
    SKYE

    Skye Bioscience, Inc.

    Feb 24, 2025
    Award(A)

    Stock Option (Right to Buy)

    Direct
    135K shares-
  • Skye Bioscience, Inc. logo
    SKYE

    Skye Bioscience, Inc.

    Nov 18, 2024
    Sale(S)
    Direct
    86.2K shares at avg. $4.99$430K
  • Skye Bioscience, Inc. logo
    SKYE

    Skye Bioscience, Inc.

    Nov 15, 2024
    Sale(S)
    Direct
    307 shares at avg. $5.55$2K
  • Skye Bioscience, Inc. logo
    SKYE

    Skye Bioscience, Inc.

    Oct 28, 2024
    Award(A)

    Stock Option (Right to Buy)

    Direct
    70K shares-

1-6 of 6

About Grayson Paul A.

Grayson Paul A. (SEC CIK 0001861554) files insider reports with the SEC as Director of Skye Bioscience, Inc. (SKYE).

Signal8 holds 5 ownership filings by Grayson Paul A., all Form 4s, filed between Oct 30, 2024 and Apr 2, 2026. Those filings report 6 transactions, from Oct 28, 2024 to Mar 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Grayson Paul A.'s filings is in SAN DIEGO, CA.

Recent filings by Grayson Paul A.

  • Mar 31, 2026: Grant or award of SKYE derivative securities (Form 4, code A).
  • Feb 6, 2026: Grant or award of SKYE derivative securities (Form 4, code A).
  • Feb 24, 2025: Grant or award of SKYE derivative securities (Form 4, code A).
  • Nov 18, 2024: Open-market sale of SKYE shares (Form 4, code S).
  • Nov 15, 2024: Open-market sale of SKYE shares (Form 4, code S).

Other insiders filing for Skye Bioscience, Inc. (SKYE)

How to read Form 4 transaction codes